Shuttle Pharmaceuticals
SHPH
7 hedge funds and large institutions have $210K invested in Shuttle Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.62% less ownership
Funds ownership: 1.35% → 0.73% (-0.62%)
59% less capital invested
Capital invested by funds: $513K → $210K (-$303K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$176K |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$52.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$36.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$30.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Connective Capital Management
Palo Alto,
California
|
-$357K |
| 2 |
DS
DRW Securities
Chicago,
Illinois
|
-$152K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$537 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
1
Ikarian Capital
Dallas,
Texas
| $124K | +$176K | +6,899 | New |
|
|
BFM
2
Boothbay Fund Management
New York
| $36.6K | +$52.1K | +2,036 | New |
|
|
3
Geode Capital Management
Boston,
Massachusetts
| $26K | +$36.9K | +1,444 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $21.5K | +$30.5K | +1,194 | +119,400% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1.46K | -$537 | -21 | -21% |
|
6
Morgan Stanley
New York
| $49 | – | – | – |
|
7
Bank of America
Charlotte,
North Carolina
| $22 | – | – | – |
|
|
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $4 | – | – | – |
|
9
Citigroup
New York
| $2 | – | – | – |
|
|
CCM
10
Connective Capital Management
Palo Alto,
California
| – | -$357K | -10,054 | Closed |
|
|
DS
11
DRW Securities
Chicago,
Illinois
| – | -$152K | -4,283 | Closed |
|
SHPH Hedge Fund Activity: Q4 2025 in Review
7 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q4 2025, worth a combined $210K — down 59% from $513K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SHPH positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $176K. The largest seller was Connective Capital Management, exiting entirely with an estimated $357K sold.
- 7 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q4 2025, up from 6 in Q3 2025.
- Funds reported $210K of Shuttle Pharmaceuticals stock for Q4 2025, down 59% quarter-over-quarter.
- 3 funds opened new Shuttle Pharmaceuticals positions in Q4 2025 and 2 closed out, a net change of +1 holder.
- The largest Shuttle Pharmaceuticals buyer in Q4 2025 was Ikarian Capital, an estimated $176K added.
- The largest Shuttle Pharmaceuticals seller in Q4 2025 was Connective Capital Management, an estimated $357K sold.
Based on aggregated 13F filings for Q4 2025.